300233 金城医药
已收盘 08-27 15:00:00
资讯
新帖
简况
8月24日金城医药跌5.08%，大成景恒混合A基金重仓该股
证券之星 · 08-24
8月24日金城医药跌5.08%，大成景恒混合A基金重仓该股
股市必读：金城医药中报 - 第二季度单季净利润同比增长873.52%
证券之星 · 08-24
股市必读：金城医药中报 - 第二季度单季净利润同比增长873.52%
金城医药（300233）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-22
金城医药（300233）2026年中报简析：营收净利润同比双双增长
金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%
证券之星 · 08-21
金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%
金城医药2026年半年报：营收结构持续优化，利润质量承压，非经常性损益占比过半
蓝鲸财经 · 08-20
金城医药2026年半年报：营收结构持续优化，利润质量承压，非经常性损益占比过半
金城医药最新公告：2026年半年度净利润同比增长220.11%
证券之星 · 08-20
金城医药最新公告：2026年半年度净利润同比增长220.11%
金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%
证券之星 · 08-05
金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%
金城医药：请参考截至2026年7月31日公司股东户数
证券之星 · 08-05
金城医药：请参考截至2026年7月31日公司股东户数
金城医药（300233）披露子公司参与全国药品集中采购拟中选公告，8月3日股价上涨1.24%
证券之星 · 08-03
金城医药（300233）披露子公司参与全国药品集中采购拟中选公告，8月3日股价上涨1.24%
金城医药最新公告：子公司注射用丁二磺酸腺苷蛋氨酸获药品注册证书
证券之星 · 07-24
金城医药最新公告：子公司注射用丁二磺酸腺苷蛋氨酸获药品注册证书
7月17日金城医药跌7.11%，大成景恒混合A基金重仓该股
证券之星 · 07-17
7月17日金城医药跌7.11%，大成景恒混合A基金重仓该股
金城医药：在研产品目前处于小试阶段
证券之星 · 07-14
金城医药：在研产品目前处于小试阶段
金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%
证券之星 · 07-10
金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%
金城医药：通过精益管理、优化组织流程提升运营效能
证券之星 · 07-10
金城医药：通过精益管理、优化组织流程提升运营效能
金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%
证券之星 · 07-09
金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%
金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%
证券之星 · 07-06
金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%
金城医药最新公告：预计上半年净利润同比增长154%-223%
证券之星 · 07-06
金城医药最新公告：预计上半年净利润同比增长154%-223%
金城医药：预计上半年净利同比增154%-223%
格隆汇 · 07-06
金城医药：预计上半年净利同比增154%-223%
金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%
证券之星 · 07-06
金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%
金城医药：公司将不断提高信息披露质量
证券之星 · 07-02
金城医药：公司将不断提高信息披露质量
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药化工、合成生物学、女性健康科技及高端抗感染领域，拓展新型烟草领域。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":13.5,"timestamp":1787814192000,"preClose":13.39,"halted":0,"volume":7105026,"delay":0,"changeRate":0.0082,"floatShares":372000000,"shares":384000000,"eps":0.3639,"marketStatus":"已收盘","change":0.11,"latestTime":"08-27 15:00:00","open":13.34,"high":13.62,"low":13.31,"amount":95766500,"amplitude":0.0232,"askPrice":13.5,"askSize":367,"bidPrice":13.49,"bidSize":268,"shortable":0,"etf":0,"ttmEps":0.3639,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":5,"adr":0,"adjPreClose":13.39,"symbolType":"stock","openAndCloseTimeList":[[1787794200000,1787801400000],[1787806800000,1787814000000]],"highLimit":14.73,"lowLimit":12.05,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.37,"roa":"--","peRate":37.098104,"roe":"3.72%","epsLYR":0.12,"committee":-0.431606,"marketValue":5182000000,"turnoverRate":0.0191,"status":0,"floatMarketCap":5025000000},"requestUrl":"/m/hq/s/300233/wiki","defaultTab":"wiki","newsList":[{"id":"2661221721","title":"8月24日金城医药跌5.08%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221721","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661221721?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:39","pubTimestamp":1787560797,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日金城医药跌5.08%，收盘报13.07元，换手率3.82%，成交量14.23万手，成交额1.89亿元。重仓金城医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661455842","title":"股市必读：金城医药中报 - 第二季度单季净利润同比增长873.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661455842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661455842?lang=zh_cn&edition=full","pubTime":"2026-08-24 02:09","pubTimestamp":1787508551,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，金城医药报收于13.77元，下跌4.51%，换手率3.87%，成交量14.33万手，成交额1.98亿元。业绩披露要点：2026年第二季度归母净利润8107.9万元，同比上升873.52%。公司公告汇总：董事会审议通过将回购股份用途由出售变更为注销，总股本拟由383,874,587股减少至379,331,587股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218988","title":"金城医药（300233）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218988","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661218988?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:14","pubTimestamp":1787350494,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期金城医药发布2026年中报。根据财报显示，金城医药营收净利润同比双双增长。截至本报告期末，公司营业总收入14.47亿元，同比上升6.4%，归母净利润1.39亿元，同比上升220.11%。投资活动产生的现金流量净额变动幅度为408.52%,原因:上期持有的结构性存款于报告期到期解付及报告期转让无形资产现金流入增加。本文数据来源于金城医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661269758","title":"金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661269758","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661269758?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:46","pubTimestamp":1787305599,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年7月31日公司股东户数为2.97万户，较6月30日增加2960.0户，增幅为11.09%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年6月30日至2026年7月31日，金城医药区间涨幅为3.87%，在此期间股东户数增加2960.0户，增幅为11.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660864422","title":"金城医药2026年半年报：营收结构持续优化，利润质量承压，非经常性损益占比过半","url":"https://stock-news.laohu8.com/highlight/detail?id=2660864422","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660864422?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:09","pubTimestamp":1787224147,"startTime":"0","endTime":"0","summary":"公司2026年半年度财报显示，营收与利润指标呈现显著分化：营业收入达14.47亿元，同比增长6.40%；归母净利润为1.39亿元，同比大幅增长220.11%；扣非净利润为0.66亿元，同比增长70.92%。营收结构持续优化，制剂业务反超原料药成为第一大收入来源头孢侧链活性酯系列产品与制剂产品合计贡献近半营业收入。此外，2026年7月，傅苗青、周白水以现金形式补偿金城金素及榄都药业已补缴税金2159.68万元及利息，增加归母净利润1516.16万元，亦构成当期非经常性收益组成部分。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787222551307939936","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660285570","title":"金城医药最新公告：2026年半年度净利润同比增长220.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660285570","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660285570?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:29","pubTimestamp":1787221799,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司发布2026年半年度报告，实现营业收入14.47亿元，同比增长6.4%；归属于上市公司股东的净利润1.39亿元，同比增长220.11%。注：公司Q2净利润0.81亿，Q1净利润0.58亿，据此计算，Q2净利润环比增长40%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000034569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510881","title":"金城医药(300233)7月31日股东户数2.97万户，较上期增加11.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510881","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657510881?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:45","pubTimestamp":1785923117,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年7月31日公司股东户数为2.97万户，较6月30日增加2960.0户，增幅为11.09%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.59万户。从股价来看，2026年6月30日至2026年7月31日，金城医药区间涨幅为3.87%，在此期间股东户数增加2960.0户，增幅为11.09%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500032491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657968855","title":"金城医药：请参考截至2026年7月31日公司股东户数","url":"https://stock-news.laohu8.com/highlight/detail?id=2657968855","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657968855?lang=zh_cn&edition=full","pubTime":"2026-08-05 08:55","pubTimestamp":1785891309,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：截止到7月10，股东人数，谢谢！金城医药回复：投资者，您好，请参考截至2026年7月31日公司股东户数。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500009679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656377735","title":"金城医药（300233）披露子公司参与全国药品集中采购拟中选公告，8月3日股价上涨1.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656377735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656377735?lang=zh_cn&edition=full","pubTime":"2026-08-03 22:40","pubTimestamp":1785768026,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，金城医药报收于13.04元，较前一交易日上涨1.24%，最新总市值为50.06亿元。近日，金城医药披露《关于子公司参与全国药品集中采购拟中选的公告》。公告显示，公司全资子公司北京金城泰尔制药有限公司的地屈孕酮片、控股子公司广东金城金素制药有限公司的注射用厄他培南钠拟中选第十二批全国药品集中采购。地屈孕酮片2026年4月获批，尚未销售；注射用厄他培南钠2025年4月获批，2025年销售收入为48.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300037710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270014","title":"金城医药最新公告：子公司注射用丁二磺酸腺苷蛋氨酸获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270014","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653270014?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:55","pubTimestamp":1784883321,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，全资子公司金城泰尔收到国家药监局下发的注射用丁二磺酸腺苷蛋氨酸《药品注册证书》，该产品视同通过仿制药一致性评价，适用于肝硬化前和肝硬化所致肝内胆汁淤积及妊娠期肝内胆汁淤积。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652147406","title":"7月17日金城医药跌7.11%，大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652147406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652147406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:50","pubTimestamp":1784278224,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日金城医药跌7.11%，收盘报12.94元，换手率5.56%，成交量20.57万手，成交额2.74亿元。重仓金城医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175695","title":"金城医药：在研产品目前处于小试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175695?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:39","pubTimestamp":1784018349,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月14日在投资者关系平台上答复投资者关心的问题。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400031150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650181267","title":"金城医药（300233）股东淄博金城实业投资股份有限公司质押660万股，占总股本1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650181267","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650181267?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:20","pubTimestamp":1783678833,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药7月10日公开信息显示，股东淄博金城实业投资股份有限公司向国泰海通证券股份有限公司合计质押660.0万股，占总股本1.72%。质押详情见下表：截止本公告日，股东淄博金城实业投资股份有限公司已累计质押股份1740.0万股，占其持股总数的22.15%。金城医药主营业务：涵盖医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售等。本文数据来源于金城医药公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000035885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907059","title":"金城医药：通过精益管理、优化组织流程提升运营效能","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907059?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:04","pubTimestamp":1783667059,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月09日在投资者关系平台上答复投资者关心的问题。后续公司将持续聚焦主营业务、提升经营业绩；通过数字化升级、绩效改革等措施提升人均产出，持续强化关键人才梯队建设，加大核心人才引育留存力度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650940990","title":"金城医药（300233）披露控股股东部分股份质押及解除质押公告，7月9日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650940990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650940990?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:18","pubTimestamp":1783588682,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，金城医药报收于13.0元，较前一交易日下跌1.74%，最新总市值为49.9亿元。近日，金城医药披露《关于控股股东部分股份质押及解除质押的公告》。公告显示，山东金城医药集团股份有限公司于2026年7月8日接到控股股东淄博金城实业投资股份有限公司通知，金城实业将其持有的公司部分股份办理了质押及解除质押业务。本次变动后，金城实业累计质押股份占其所持股份比例为26.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900030268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649627223","title":"金城医药（300233）披露2026年半年度业绩预告，7月6日股价上涨0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649627223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649627223?lang=zh_cn&edition=full","pubTime":"2026-07-06 22:36","pubTimestamp":1783348581,"startTime":"0","endTime":"0","summary":"截至2026年7月6日收盘，金城医药报收于13.41元，较前一交易日上涨0.68%，最新总市值为51.48亿元。近日，山东金城医药集团股份有限公司发布2026年半年度业绩预告，预计2026年1月1日至6月30日归属于上市公司股东的净利润为11,000.00万元至14,000.00万元，同比增长153.55%至222.71%；扣除非经常性损益后的净利润为6,000万元至8,000万元，同比增长54.92%至106.56%。该数据未经注册会计师审计，最终数据以2026年半年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600037726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649623574","title":"金城医药最新公告：预计上半年净利润同比增长154%-223%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649623574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649623574?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:20","pubTimestamp":1783333209,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，预计2026年半年度归属于上市公司股东的净利润为1.10亿元-1.40亿元，同比增长153.55%-222.71%。业绩变动主要系中间体板块部分产品销量增加、产能利用率提高及非经常性损益增加所致。注：公司Q2净利润预计0.52亿-0.82亿，Q1净利润0.58亿，据此计算，Q2净利润预计环比变动-9%-42%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600028214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649623522","title":"金城医药：预计上半年净利同比增154%-223%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649623522","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649623522?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:15","pubTimestamp":1783332931,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300233","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640285","title":"金城医药(300233)6月30日股东户数2.67万户，较上期减少0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640285","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649640285?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:36","pubTimestamp":1783330595,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2026年6月30日公司股东户数为2.67万户，较6月10日减少213.0户，减幅为0.79%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年6月10日至2026年6月30日，金城医药区间涨幅为2.48%，在此期间股东户数减少213.0户，减幅为0.79%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648001025","title":"金城医药：公司将不断提高信息披露质量","url":"https://stock-news.laohu8.com/highlight/detail?id=2648001025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648001025?lang=zh_cn&edition=full","pubTime":"2026-07-02 20:51","pubTimestamp":1782996711,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药07月01日在投资者关系平台上答复投资者关心的问题。不要用业绩回报这种空洞说辞搪塞金城医药回复：投资者，您好，感谢您的关注。公司高度重视市值管理工作，公司将不断提高信息披露质量，确保信息披露的真实、准确、完整；在投资者交流方面，公司通过投资者服务电话、业绩说明会、互动易平台等方式回应投资者诉求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200039637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787826744592,"stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":0.0568},{"period":"3month","weight":0.0284},{"period":"6month","weight":-0.1153},{"period":"1year","weight":-0.3152},{"period":"ytd","weight":-0.0337}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0141},{"period":"3month","weight":-0.0454},{"period":"6month","weight":-0.0601},{"period":"1year","weight":0.0114},{"period":"ytd","weight":-0.0142}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"29656人(较上一季度增加11.09%)","perCapita":"12551股","listingDate":"2011-06-22","address":"山东省淄博市淄川区淄川经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药化工、合成生物学、女性健康科技及高端抗感染领域，拓展新型烟草领域。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}